Article

Alcon third-quarter profit increases by 51%

Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year.

Hunenberg, Switzerland-Alcon's quarterly earnings per share came in above analysts' expectations and rose 51% from last year. The company also lowered its revenue guidance, while raising its earnings outlook for the full year 2008.

The reported net income for the third quarter was $627.1 million or $2.07 per share, higher than last year's $415.3 million or $1.38 per share for the third quarter, said the company in a prepared statement. The net earnings for the most recent quarter included a $239.5 million tax benefit associated with losses on the value of the company's investment in and advances to the former Summit Autonomous Inc.

Sales for the quarter rose 14.1% to $1.52 billion from $1.34 billion in the prior-year quarter, while analysts had a revenue consensus of $1.54 billion, according to the company. The acquisition of WaveLight AG contributed 1.4 percentage points of sales growth in the third quarter.

Consumer eye-care sales for the quarter increased 10.5% to $223.7 million. Sales of contact lens disinfectants grew 2.6% and sales of artificial tears products increased 28%, said the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.